Brunac (Acetylcysteine) is generally applied for symptomatic relief in conditions presenting with systemic or localized discomfort where the primary challenge is the presence of abnormally thick and tenacious mucus in the respiratory tract. This agent is used to manage conditions characterized by abnormal, viscid, or inspissated mucous secretions.

The medication is commonly used across several therapeutic domains, including supportive management for chronic conditions like Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis, and Cystic Fibrosis, as well as during acute episodes such as tracheobronchitis or pneumonia. Furthermore, it is applied in specialized clinical scenarios for patients with a tracheostomy or those on mechanical ventilation. Its primary role is relevant for easing the physical discomfort and difficulty patients experience when attempting to clear the chest.

“The supportive role of this medicine may assist in easing the overall symptom load and contributes to improved day-to-day comfort, especially during periods of heightened respiratory discomfort.”

This focus on supporting secretion management may help patients cope more steadily with symptoms that interfere with functional stability.

---

Quick Fact: Symptomatic Support for Thick, Difficult-to-Clear Sputum

---

Regulatory References

1. DailyMed Label for Acetylcysteine Inhalant

Who can and cannot use Brunac (EXPECTORANT)?

The eligibility for using Brunac (Acetylcysteine) is strictly defined by official regulatory documents, which establish clear boundaries for who may use the medicine and who is formally excluded. This guidance focuses solely on documented population eligibility and non-eligibility rules.

Population Category	Official Eligibility Status
Contraindicated	Known hypersensitivity to Acetylcysteine or excipients. Children under 2 years for the mucolytic use.
Conditional Use	Patients with bronchial asthma, peptic ulceration history, or severe hepatic/renal impairment require caution.
Not Recommended	Individuals who are pregnant or breastfeeding.
Allowed Age Groups	Adults, adolescents, and children 2 years and above.

Official Eligibility Statements

The medicine is contraindicated in patients with a recognized hypersensitivity to the drug and, for the mucolytic indication, in children younger than 2 years of age. Use requires caution in patients with a history of peptic ulceration or bronchial asthma, necessitating close monitoring. Furthermore, use during both pregnancy and lactation is generally not recommended due to a lack of established safety data in these physiological states. This profile creates a strict, regulatory-defined boundary for acceptable use.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Brunac (Acetylcysteine) around specific pharmacodynamic conflicts, chemical incompatibilities, and exposure modifications of co-administered medicines.

Documented Interaction Patterns

The co-administration of Acetylcysteine with antitussive medicinal products is strongly advised against. This is due to a pharmacodynamic conflict where the suppression of the cough reflex can lead to the dangerous buildup of bronchial secretions.

Acetylcysteine can potentiate the effects of organic nitrates, such as Nitroglycerin, which is officially described as increasing the risk of hypotension and headache. Concomitant use with Carbamazepine may result in sub-therapeutic levels of Carbamazepine.

Administration Restrictions

To prevent in vitro chemical inactivation, certain oral antibiotics (including some Penicillins and Cephalosporins) must be administered at least two hours before or after Acetylcysteine. Similarly, heavy metal salts (e.g., salts of gold, iron, and potassium) must be taken at a different time of the day. When used as an antidote, Acetylcysteine should be administered at least one hour after Activated Charcoal to preserve its absorption. It is also advised not to mix Acetylcysteine with any other product in a nebulizer.

Formulation-Specific Restrictions

Certain formulations contain Aspartame, which is a source of phenylalanine, and is an official restriction for individuals with Phenylketonuria (PKU). Formulations containing Sorbitol carry a restriction for patients with hereditary fructose intolerance.

Mechanism of Action: Brunac (EXPECTORANT)

Mucolytic Depolymerization

Brunac, containing N-acetylcysteine, functions as a mucolytic agent through direct chemical interaction with respiratory secretions. The active ingredient utilizes its free sulfhydryl ( -SH) group as a reducing agent to cleave the disulfide ( S-S) bonds structuring mucin glycoproteins. The breakdown of this polymer network results in a reduction in the viscosity and elasticity of the tenacious bronchial mucus.

---

Modulation of Clearance and Cellular Redox

By reducing mucus viscosity, the drug facilitates mucociliary clearance, supporting the transport and removal of secretions by the body's natural ciliary movement. Furthermore, the active ingredient acts as a precursor for the essential endogenous antioxidant glutathione ( GSH). This precursor role assists the cellular redox pathway, helping to modulate cellular redox balance and affect the consequences of oxidative stress in airway tissues.

Brunac (Acetylcysteine) is administered through two primary routes as a mucolytic agent: oral intake and inhalation via nebulization. The route determines the required dosage form, which includes oral preparations like effervescent tablets and solutions, or a sterile solution specifically designed for nebulization.

For oral administration in adults, the standardized regimen often involves either a divided dose or a single daily dose. A common pattern is 200 mg taken two to three times per day. For long-term use, especially in chronic conditions, the regimen may involve a single dose of 600 mg once daily. Effervescent tablets must be completely dissolved in a half-glass of drinking water before consumption. Oral administration is generally independent of meal timing.

Inhalational use is typically scheduled for three to four times daily. The dose ranges from 3 mL to 5 mL of a 20% solution or 6 mL to 10 mL of a 10% solution per treatment. Prior to use, the solution may require dilution with sterile water or saline to ensure proper nebulization. Procedural constraints stipulate that the inhalant solution should only be administered using nebulizers with glass or plastic components, avoiding contact with iron or copper materials.

Specific rules exist for pediatric administration, requiring lower doses, such as 100 mg to 200 mg two to three times daily. The duration of use is categorized as either a short-term course (e.g., 5 to 10 days) for acute instances or as long-term maintenance therapy for chronic respiratory conditions. If a dose is missed, the regular schedule should be resumed with the next dose, without attempting to double the amount.

Research Evidence / Overview of Studies

Research on Efficacy

Research has explored the use of Brunac (acetylcysteine), a mucolytic agent, primarily in respiratory conditions characterized by thick, viscous mucus, such as chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD).

Studies have investigated the drug's relationship with sputum viscosity and the difficulty of expectoration.

Key Findings on Mucociliary Clearance

Area of Investigation	Summary of Findings
Sputum Viscosity	One large, multicenter, randomized controlled study reported a statistically significant superiority of intravenous acetylcysteine over placebo in reducing sputum viscosity scores after one week.
Exacerbations (CB/COPD)	Systematic reviews and meta-analyses, including studies with over 4,000 patients, have investigated the potential role of oral acetylcysteine in reducing the frequency of exacerbations (flare-ups) in individuals with Chronic Bronchitis and COPD.

Safety and Tolerability Profile

Clinical trials have monitored common effects across oral and intravenous administrations. The most frequently observed adverse events in oral formulations relate to mild gastrointestinal effects such as nausea, vomiting, or dyspepsia. Severe or unexpected safety concerns were not documented within the specific parameters examined in most recent large-scale trials.

Special Populations

Research has explored the drug's profile over a long-term period, including studies lasting up to 52 weeks, to assess its extended use profile. Due to the difficulty children may have in actively coughing up loosened mucus, the use of mucolytics in children under two years old is often approached with caution.

Key Studies & References

1. Label: ACETYLCYSTEINE solution (FDA/DailyMed, Mucolytic Uses)
2. Study Details | NCT01599884 | N-Acetylcysteine for Patients With COPD and Chronic Bronchitis | ClinicalTrials.gov
3. N-Acetylcysteine (NAC): Impacts on Human Health (Review of Pharmacokinetics and Safety)

Common questions about Brunac (EXPECTORANT) (FAQ)

Q: Is it okay to drive or operate machinery after taking Brunac?

A: Official product information states that no specific studies have been performed to assess the medicine's effect on the ability to drive or use machines. However, official labels generally do not report a known effect of the medicine on the ability to drive or use machines.

---

Q: Is this medicine safe to use for a cold or the flu?

A: Regulatory labels define the use of Acetylcysteine as an add-on treatment for patients who have abnormal, thick mucous secretions due to chronic bronchopulmonary disorders. The medicine's official indications do not typically list the common cold or the flu as specific conditions for which it should be used.

---

Q: Do I need a prescription to get Brunac?

A: Regulatory labeling often indicates that the sterile solution form of Acetylcysteine, which is used for inhalation or oral administration as a mucolytic, is available by prescription. The actual method of purchase depends on the specific country, region, and the particular formulation being sold.

---

Q: What specific conditions or diseases is Brunac used to treat?

A: The medicine is indicated as an adjunct (additional) treatment for conditions associated with abnormal, viscid, or very thick mucous secretions, such as chronic bronchopulmonary disorders. This function is clinically recognized for improving airway flow.

---

Q: What if I miss a dose of the medicine?

A: Official instructions advise that if a dose of the medicine is missed, you should continue with the regular schedule at the time of the next planned dose and not attempt to take a double dose to compensate for the one you missed.

---

Q: What is the recommended dose for an adult taking it orally?

A: Official documentation outlines the dosage patterns for adults, which may involve divided daily doses or a single daily dose for long-term use in chronic conditions. The appropriate dosage and regimen must be determined by the healthcare prescriber.

---

Q: What is the typical duration of use for this medicine?

A: Regulatory documents define the duration of treatment based on the specific condition being managed. Use may be specified as a short-term course for acute instances or as long-term maintenance therapy for chronic respiratory disorders.

How to Store and Dispose of Brunac (Acetylcysteine)

The storage and disposal of Brunac must strictly follow the conditions mandated by regulatory labeling to maintain product stability and ensure safety.

---

Storage Requirements

• Temperature: Unopened product should be stored at controlled room temperature, mathbf20-25 C (mathbf68-77 F). The solution for nebulization must not be frozen.
• Handling: The medicine must be protected from light and stored in its original container, kept tightly closed.
• Child Safety: Brunac must be kept out of the sight and reach of children.
• Stability: Opened, undiluted solution for nebulization must be refrigerated at mathbf2^circ to mathbf8 C and is stable for 96 hours (4 days), after which it must be discarded.

---

Disposal Instructions

• Discard any unused portion of opened solution that exceeds the 96-hour stability limit.
• Disposal of all expired or unused medicine and its container must be performed in accordance with local, regional, and national regulations.